MODULATION OF LIPOPOLYSACCHARIDE-INDUCED MACROPHAGE GENE-EXPRESSION BY RHODOBACTER-SPHAEROIDES LIPID-A AND SDZ-880.431

被引:21
作者
MANTHEY, CL
PERERA, PY
QURESHI, N
STUTZ, PL
HAMILTON, TA
VOGEL, SN
机构
[1] UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814
[2] UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BACTERIOL,MADISON,WI 53706
[3] WILLIAM S MIDDLETON MEM VET ADM MED CTR,MYCOBACTERIOL RES LAB,MADISON,WI 53705
[4] SANDOZ GMBH,A-1235 VIENNA,AUSTRIA
[5] CLEVELAND CLIN EDUC FDN,RES INST,DEPT IMMUNOL,CLEVELAND,OH 44106
关键词
D O I
10.1128/IAI.61.8.3518-3526.1993
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rhodobacter sphaeroides lipid A (RsDPLA) and SDZ 880.431 (3-aza-lipid X4-phosphate) are prototypic lipopolysaccharide (LPS) antagonists. Herein, we examined the ability of these structures to regulate murine macrophage tumor necrosis factor (TNF) secretion and LPS-inducible gene expression (tumor necrosis factor alpha [TNF-alpha], interleukin-1beta [IL-1beta], IP-10, type 2 TNF receptor [TNFR-2], D3, and D8 genes). We report that RsDPLA alone (> 1 mug/ml) induced low levels of TNF-alpha secretion and a selective pattern of gene expression in peritoneal exudate macrophages; SDZ 880.431 alone was completely inactive. When LPS was present at a low concentration (1 ng/ml), RxDPLA and SDZ 880.431 blocked TNF secretion and gene induction in a concentration-dependent fashion. In general, gene induction was measurably reduced by 10 to 30 ng of RsDPLA per ml or 300 ng of SDZ 880.431 per ml, but inhibition could be uniformly overridden by increasing the concentration of LPS. Although induction of all six genes by LPS was suppressed by either inhibitor, effective inhibitor concentrations depended on the gene of interest. Induction of TNFR-2 by LPS was relatively resistant to inhibition by RxDPLA, and induction of TNFR-2 and D3 was relatively resistant to inhibition by SDZ 880.431. When LPS was present at greater-than-or-equal-to 100 ng/ml, correspondingly high concentrations (greater-than-or-equal-to 20 mug/ml) of either inhibitor influenced gene expression in a bidirectional manner. Under these conditions, LPS-induced expression of IP-10, D3, and D8 was suppressed regardless of the LPS concentration used (concentrations tested up to 50 mug/ml), while expression of TNF-alpha mRNA was enhanced about fourfold. In toto, RsDPIA and SDZ 880.431, when present at low concentrations, act in a manner consistent with competitive inhibition of LPS, while at higher concentrations, these structures inhibit certain LPS responses noncompetitively and synergize with LPS for other responses.
引用
收藏
页码:3518 / 3526
页数:9
相关论文
共 46 条
[1]   STRUCTURAL FEATURES THAT INFLUENCE THE ABILITY OF LIPID-A AND ITS ANALOGS TO ABOLISH EXPRESSION OF SUPPRESSOR T-CELL ACTIVITY [J].
BAKER, PJ ;
HRABA, T ;
TAYLOR, CE ;
MYERS, KR ;
TAKAYAMA, K ;
QURESHI, N ;
STUETZ, P ;
KUSUMOTO, S ;
HASEGAWA, A .
INFECTION AND IMMUNITY, 1992, 60 (07) :2694-2701
[2]  
GAUTAM S, 1992, J IMMUNOL, V148, P1725
[3]  
GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490
[4]   ENZYMATIC DEACYLATION OF THE LIPID-A MOIETY OF SALMONELLA-TYPHIMURIUM LIPOPOLYSACCHARIDES BY HUMAN-NEUTROPHILS [J].
HALL, CL ;
MUNFORD, RS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (21) :6671-6675
[5]  
HAMILTON TA, 1989, J IMMUNOL, V142, P2325
[6]   DISSOCIATION OF LIPOPOLYSACCHARIDE (LPS)-INDUCIBLE GENE-EXPRESSION IN MURINE MACROPHAGES PRETREATED WITH SMOOTH LPS VERSUS MONOPHOSPHORYL LIPID-A [J].
HENRICSON, BE ;
MANTHEY, CL ;
PERERA, PY ;
HAMILTON, TA ;
VOGEL, SN .
INFECTION AND IMMUNITY, 1993, 61 (06) :2325-2333
[7]   RHODOPSEUDOMONAS-SPHAEROIDES LIPID-A DERIVATIVES BLOCK INVITRO INDUCTION OF TUMOR-NECROSIS-FACTOR AND ENDOTOXIN TOLERANCE BY SMOOTH LIPOPOLYSACCHARIDE AND MONOPHOSPHORYL LIPID-A [J].
HENRICSON, BE ;
PERERA, PY ;
QURESHI, N ;
TAKAYAMA, K ;
VOGEL, SN .
INFECTION AND IMMUNITY, 1992, 60 (10) :4285-4290
[8]  
HEUMANN D, 1992, J IMMUNOL, V148, P3505
[9]  
HOGAN MM, 1990, CURRENT PROTOCOLS IM, V1
[10]  
HOMMA J Y, 1989, Drugs of the Future, V14, P645